CoLucid Pharmaceuticals Inc.

(CLCD) Trade

By |

Profile

CoLucid Pharmaceuticals Inc was incorporated on August 31, 2005. It is a Phase 3 clinical-stage biopharmaceutical company that is developing a proprietary small molecule for the acute treatment of migraine headaches. Its product candidates utilize the first new mechanism of action in the last twenty years, which it believes could address the unmet needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those who are dissatisfied with existing therapies. Lasmiditan, its product candidate, is an oral tablet for the acute treatment of migraine headaches in adults that does not have the clinical limitations associated with the commonly used therapies. It is also developing intravenous lasmiditan, or IV lasmiditan, for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings, another unmet medical need. The Company does not have a sales, marketing or drug distribution infrastructure. It currently contracts with third parties for the manufacture, testing and storage of its product candidates. It owns or has exclusive rights to a patent portfolio related to the manufacture, sale and use of lasmiditan and IV lasmiditan. Its trademark includes CoLucid and the CoLucid logo.

Contact Information

Website: www.colucid.com
Email: hans@lifesciadvisors.com
Main Phone: +1 857 285-6495
Address: 222 Third Street
Address 2: Suite 1320
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NSD
CEO: Thomas P. Mathers
Employees: 7
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

CoLucid Pharmaceuticals Inc was incorporated on August 31, 2005. It is a Phase 3 clinical-stage biopharmaceutical company that is developing a proprietary small molecule for the acute treatment of migraine headaches. Its product candidates utilize the first new mechanism of action in the last twenty years, which it believes could address the unmet needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those who are dissatisfied with existing therapies. Lasmiditan, its product candidate, is an oral tablet for the acute treatment of migraine headaches in adults that does not have the clinical limitations associated with the commonly used therapies. It is also developing intravenous lasmiditan, or IV lasmiditan, for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings, another unmet medical need. The Company does not have a sales, marketing or drug distribution infrastructure. It currently contracts with third parties for the manufacture, testing and storage of its product candidates. It owns or has exclusive rights to a patent portfolio related to the manufacture, sale and use of lasmiditan and IV lasmiditan. Its trademark includes CoLucid and the CoLucid logo.

Contact Information

Website: www.colucid.com
Email: hans@lifesciadvisors.com
Main Phone: +1 857 285-6495
Address: 222 Third Street
Address 2: Suite 1320
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NSD
CEO: Thomas P. Mathers
Employees: 7
NAICS: Pharmaceutical Preparation Manufacturing(325412)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi 46.65 52 Wk Low 5.26
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 19,284,290.00 EPS (TTM) -3.25 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Thomas P. Mathers 1,000
Arthur M. Pappas 1,000
Arthur M. Pappas 1,000
Luc Marengere 1,000
Last 10 Sell Shares
Linda C. Hogan 1,000
Linda C. Hogan 1,000
Linda C. Hogan 1,000
Thomas P. Mathers 1,000
Thomas P. Mathers 1,000
Thomas P. Mathers 1,000
Linda C. Hogan 1,000
Matthew Dallas 1,000
Bernice Kuca 1,000
Linda C. Hogan 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 46.5 46.5 46.5 46.5
Low Target Price Estimate 36 36 36 36
Mean Target Price Estimate 42.5 42.5 42.5 42.5
Standard Deviation 5.68 5.68 5.68 5.68
Date of Most Recent Estimate 01/23/17 01/23/17 01/23/17 01/23/17
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 4 4
Moderate Buy 0 0 0 0
Hold 4 4 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3 3 1 1